| Q33763449 | A focus on intra-abdominal infections |
| Q31034219 | A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. |
| Q38189330 | A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa |
| Q44936182 | Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings |
| Q34795807 | Acinetobacter baumannii: emergence of a successful pathogen |
| Q37037407 | Acinetobacter pneumonia: a review. |
| Q37845845 | Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104. |
| Q34579696 | An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. |
| Q30408712 | Antibiotic stewardship in the intensive care unit |
| Q44580623 | Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America |
| Q36022817 | Association between β-lactamase-encoding bla(OXA-51) variants and DiversiLab rep-PCR-based typing of Acinetobacter baumannii isolates |
| Q36382134 | Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America |
| Q44944388 | Carbapenem resistance and Acinetobacter baumannii |
| Q46510582 | Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents |
| Q35543013 | Carbapenems in Pediatrics |
| Q42167294 | Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals |
| Q42202436 | Clinical features and risk factors for development of Bacillus bacteremia among adult patients with cancer: a case-control study |
| Q28299749 | Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use |
| Q40777387 | Colistin, an Old Drug in a New Territory, Solid Organ Transplantation |
| Q46109545 | Collateral damage of cephalosporins and quinolones and possibilities for control |
| Q28221069 | Control of an outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation |
| Q41653972 | Control of hospital endemicity of multiple-drug-resistant Acinetobacter baumannii ST457 with directly observed hand hygiene |
| Q37385015 | Correlation between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a medical-surgical intensive care unit |
| Q39608636 | Costs and Mortality Associated With Multidrug-Resistant Healthcare-Associated Acinetobacter Infections |
| Q21135285 | Deciphering the multifactorial nature of Acinetobacter baumannii pathogenicity |
| Q34042310 | Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. |
| Q37958558 | Development of immunization trials against Klebsiella pneumoniae. |
| Q40053545 | Distribution of Class D Carbapenemase and Extended-Spectrum β-Lactamase Genes among Acinetobacter Baumannii Isolated from Burn Wound and Ventilator Associated Pneumonia Infections |
| Q34601684 | Drug treatment for multidrug-resistant Acinetobacter baumannii infections. |
| Q53845615 | Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test. |
| Q24538871 | Evaluation of techniques for detection of carbapenem-resistant Klebsiella pneumoniae in stool surveillance cultures |
| Q33254871 | Extensive genomic plasticity in Pseudomonas aeruginosa revealed by identification and distribution studies of novel genes among clinical isolates |
| Q42656903 | Genetic relatedness of multidrug-resistant Acinetobacter baumannii endemic to New York City |
| Q54600879 | Genotypic analysis of Acinetobacter bloodstream infection isolates in a Turkish university hospital. |
| Q36095081 | Global challenge of multidrug-resistant Acinetobacter baumannii |
| Q36667930 | Gram-negative antibiotic resistance: there is a price to pay. |
| Q22241905 | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia |
| Q38471963 | Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species |
| Q38461269 | Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes |
| Q37733474 | In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains |
| Q43252105 | In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore |
| Q42695527 | In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii |
| Q40019977 | In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan. |
| Q34648729 | Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates |
| Q35994243 | Limiting the spread of highly resistant hospital-acquired microorganisms via critical care transfers: a simulation study |
| Q37439554 | Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive "bundle" approach. |
| Q41811253 | Longitudinal epidemiology of multidrug-resistant (MDR) Acinetobacter species in a tertiary care hospital |
| Q46384221 | Modelling time-kill studies to discern the pharmacodynamics of meropenem |
| Q40196177 | Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant Acinetobacter baumannii infection in an Israeli hospital. |
| Q49958760 | Molecular characterization of β-lactamase genes in clinical isolates of carbapenem-resistant Acinetobacter baumannii |
| Q44408903 | Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City |
| Q36313186 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals |
| Q36295402 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals |
| Q35690304 | Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. |
| Q33711902 | Multidrug resistant Acinetobacter |
| Q28306885 | Multidrug-resistant Acinetobacter baumannii |
| Q35873386 | Multidrug-resistant Acinetobacter extremity infections in soldiers |
| Q35848861 | Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians |
| Q46385050 | Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. |
| Q24681877 | Multilocus sequence typing compared to pulsed-field gel electrophoresis for molecular typing of Pseudomonas aeruginosa |
| Q40291140 | Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents |
| Q34352265 | Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents |
| Q34228382 | Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa |
| Q45285519 | Persistent Acinetobacter baumannii? Look inside your medical equipment |
| Q43236884 | Prescription of antibiotics in intensive care units in Latin America: an observational study. |
| Q35270290 | Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model |
| Q36804312 | Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology |
| Q37785546 | Resistant pathogen-associated skin and skin-structure infections: antibiotic options |
| Q51818859 | Serum resistance and biofilm formation in clinical isolates of Acinetobacter baumannii. |
| Q36247318 | Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance |
| Q34042171 | Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii |
| Q27683945 | Structure of the Acinetobacter baumannii Dithiol Oxidase DsbA Bound to Elongation Factor EF-Tu Reveals a Novel Protein Interaction Site |
| Q39878469 | Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae |
| Q34941008 | Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001 |
| Q40894742 | Tetanus in Ho Chi Minh City, Vietnam: epidemiological, clinical and outcome features of 389 cases at the Hospital for Tropical Diseases |
| Q37069191 | The current state of multidrug-resistant gram-negative bacilli in North America |
| Q36382140 | The epidemiology and control of Acinetobacter baumannii in health care facilities |
| Q42758515 | The mutL mutation in Pseudomonas aeruginosa isolates reveals multidrug-resistant traits and possible evolutionary trends |
| Q46700889 | The role of nitric oxide in resistance to P. aeruginosa ocular infection |
| Q30433201 | The state of the science |
| Q37624613 | The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii |
| Q28247555 | Tigecycline: a new glycylcycline antimicrobial agent |
| Q41869243 | Treatment of wounds colonized by multidrug resistant organisms in immune-compromised patients: a retrospective case series |
| Q36607401 | Treatment options for multidrug-resistant bacteria. |
| Q79291069 | Use of Parenteral Colistin for the Treatment of Serious Infection Due to Antimicrobial-Resistant Pseudomonas aeruginosa |
| Q36260950 | Use of antimicrobial agents in veterinary medicine and implications for human health |
| Q35793194 | VEB-1 Extended-spectrum beta-lactamase-producing Acinetobacter baumannii, France |
| Q53922003 | [Management of an outbreak of infections due to Pseudomonas aeruginosa] |